| Drug ID: | Drug103 |
|---|---|
| Drug Name: | Rifaximin |
| CID: | 6436173 |
| DrugBank ID: | DB01220 |
| Modality: | Small Molecule |
| Groups: | approved|investigational |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT00355602 |
| Molecular Formula: | C43H51N3O11 |
| Molecular Weight: | 785.9 g/mol |
| Isomeric SMILES: | C[C@H]1/C=C/C=C(\\C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)O[C@@](C4=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)/C |
| Synonyms: | Rifaximin; Rifaxidin; 80621-81-4; Rifacol; Rifamycin L 105; Rifaximine; Fatroximin; Rifamixin; Rifaximina; Normix |
| Phase 0: | 4 |
| Phase 1: | 20 |
| Phase 2: | 73 |
| Phase 3: | 50 |
| Phase 4: | 32 |
| Description: | Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It is used to treat diarrhea caused by E. coli. |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt880 | 6436173 | Rifaximin | 8856 | NR1I2 | Homo sapiens (human) | None | |
| dt881 | 6436173 | Rifaximin | 93777907 | rpoB | Escherichia coli K-12 | Inhibitor | |
| dt882 | 6436173 | Rifaximin | 8856 | NR1I2 | Homo sapiens (human) | Agonist | |
| dt883 | 6436173 | Rifaximin | 1576 | CYP3A4 | Homo sapiens (human) | Substrate|Inducer | |
| dt884 | 6436173 | Rifaximin | 1557 | CYP2C19 | Homo sapiens (human) | Inducer | |
| dt885 | 6436173 | Rifaximin | 1558 | CYP2C8 | Homo sapiens (human) | 11996015 | Inducer |
| dt886 | 6436173 | Rifaximin | 8856 | NR1I2 | Homo sapiens (human) | 22790967 | [NR1I2 results in increased susceptibility to rifaximin] which results in increased expression of CD36 protein|[nr1i2 results in increased susceptibility to rifaximin] which results in increased expression of CFD mrna|[nr1i2 results in increased susceptib |
| dt887 | 6436173 | Rifaximin | 8856 | NR1I2 | Homo sapiens (human) | 21599020 | [rifaximin binds to and results in increased activity of NR1I2 protein] inhibits the reaction [trinitrobenzenesulfonic acid results in increased expression of TNF protein]|[rifaximin binds to and results in increased activity of NR1I2 protein] inhibits th |
| dt888 | 6436173 | Rifaximin | 8856 | NR1I2 | Homo sapiens (human) | Rifaximin results in increased activity of NR1I2 protein | |
| dt889 | 6436173 | Rifaximin | 8856 | NR1I2 | Homo sapiens (human) | Rifaximin results in increased expression of NR1I2 mRNA |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT05453916 | Comparing the Efficacy of Nitazoxanide Versus Rifaximin in Adult Patients With Irritable Bowel Syndrome Without Constipation | PHASE1|PHASE2 | WITHDRAWN | Sadat City University | Irritable Bowel Syndrome With Diarrhea | DRUG: Nitazoxanide 500Mg Oral Tablet|DRUG: Rifaxi… | Details |
| NCT04841980 | Rifaximin Therapy vs Low FODMAP Diet In IBS | PHASE4 | UNKNOWN | University of Malaya | Irritable Bowel Syndrome|Small Intestinal Bacteri… | DRUG: Rifaximin|OTHER: Low FODMAP diet | Details |
| NCT04557215 | Efficacy and Safety of Rifaximin With NAC in IBS-D | PHASE1|PHASE2 | COMPLETED | Cedars-Sinai Medical Center | Irritable Bowel Syndrome With Diarrhea | DRUG: Rifaximin|DRUG: N-acetylcysteine|DRUG: Plac… | Details |
| NCT04316806 | Effect of a Probiotic Formula on Reducing SIBO in IBS Patients | NA | TERMINATED | AB Biotics, SA | Irritable Bowel Syndrome|Small Intestinal Bacteri… | DIETARY_SUPPLEMENT: Probiotic|DRUG: Rifaximin | Details |
| NCT04254549 | Rifaximin in Patients With Diabetic Gastroparesis | PHASE2 | TERMINATED | Mayo Clinic | Crohn Disease|Diabetic Gastroparesis | DRUG: Rifaximin|DRUG: Placebo | Details |
| NCT04154735 | Autologous Transplant Targeted Against Crohn's | PHASE2 | WITHDRAWN | Northwestern University | Crohn's Disease | DRUG: Fludarabine|DRUG: Cyclophosphamide|DRUG: Me… | Details |
| NCT04074421 | Effects of Continuous Treatment With Rifaximin and Probiotics on the Gut Microbiota of Patients With IBS-D | PHASE4 | UNKNOWN | Second Affiliated Hospital, School of Medicine, Zhejiang University | IBS - Irritable Bowel Syndrome|Gut Microbiota | DRUG: Rifaximin|DRUG: Probiotic Formula|DRUG: Pla… | Details |
| NCT03729271 | Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea | PHASE4 | COMPLETED | University of Michigan | Irritable Bowel Syndrome|Irritable Bowel Syndrome… | DRUG: Rifaximin|DEVICE: Glucose and lactulose hyd… | Details |
| NCT03557788 | Changes in Microbiota and Metabolomic Profile Between Rifaximin Responders and Non-responders In Diarrhoea-Predominant Irritable Bowel Syndrome | PHASE4 | COMPLETED | National University Hospital, Singapore | Irritable Bowel Syndrome With Diarrhea | DRUG: Rifaximin Oral Tablet | Details |
| NCT03537157 | A Multicentre Study on Rifaximin in Post-operative Endoscopic Crohn's Disease Recurrence Prevention | PHASE2 | TERMINATED | Alfasigma S.p.A. | Crohn Disease | DRUG: Rifaximin delayed release tablets|OTHER: Pl… | Details |
| NCT03462966 | Rifaximin on Visceral Hypersensitivity | PHASE2 | TERMINATED | Cedars-Sinai Medical Center | Visceral Hypersensitivity|Irritable Bowel Syndrome | DRUG: Rifaximin | Details |
| NCT03219528 | A Longitudinal Study to Identify IBS Phenotypes Using Fecal Microbiota and Hydrogen Breath Testing | PHASE4 | COMPLETED | University of Michigan | Irritable Bowel Syndrome | DRUG: Rifaximin 550 MG|OTHER: Low FODMAP Diet | Details |
| NCT03185624 | Effectiveness of Rifaximin on Preventing Postoperative Recurrence in Crohn's Disease | PHASE3 | UNKNOWN | Sixth Affiliated Hospital, Sun Yat-sen University | Crohn Disease | DRUG: Rifaximin | Details |
| NCT03185611 | Effectiveness of Rifaximin Combined With Thiopurine on Preventing Postoperative Recurrence in Crohn's Disease | PHASE3 | UNKNOWN | Sixth Affiliated Hospital, Sun Yat-sen University | Crohn Disease | DRUG: Rifaximin|DRUG: Azathioprine | Details |
| NCT02651740 | Gut Microbiota Reconstruction in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea | PHASE2|PHASE3 | UNKNOWN | Shanghai Zhongshan Hospital | Irritable Bowel Syndrome | DRUG: Rifaximin|PROCEDURE: Fecal microbiota trans… | Details |
| NCT02620007 | Evaluation of Adherent Invasive E. Coli Eradication in Adult Crohn Disease | PHASE2 | TERMINATED | Assistance Publique - Hôpitaux de Paris | Crohn Disease|Adherent-invasive E. Coli | DRUG: Ciprofloxacin|DRUG: Rifaximin|DRUG: Ciprofl… | Details |
| NCT02565654 | Efficacy of Rifaximin to Treat Diarrhea-predominant Irritable Bowel Syndrome | NULL | UNKNOWN | First Affiliated Hospital, Sun Yat-Sen University | Irritable Bowel Syndrome | None | Details |
| NCT02272868 | Fecal Microbial Transplant in Pediatric Crohn's Disease | PHASE1|PHASE2 | TERMINATED | Seattle Children's Hospital | Crohn's Disease | BIOLOGICAL: Fecal Microbial transplant|DRUG: Norm… | Details |
| NCT02240121 | One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease | PHASE3 | TERMINATED | Bausch Health Americas, Inc. | Crohn's Disease | DRUG: Rifaximin EIR|DRUG: Placebo | Details |
| NCT02240108 | One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease | PHASE3 | TERMINATED | Bausch Health Americas, Inc. | Crohn's Disease | DRUG: Rifaximin EIR|DRUG: Placebo | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| 2.0 | ulcerative colitis | A colitis that is predominantly confined to the mucosa located_in colon and includes characteristic ulcers, or open sores. | disease of anatomical entity, gastrointestinal system disease, autoimmune disease of gastrointestinal tract; intestinal disease, inflammatory bowel disease, colitis; disease, primary immunodeficiency disease, autoimmune disease, autoimmune disease of gastrointestinal tract | Mirikizumab; Olsalazine; Balsalazide; Sulfasalazine; Budesonide; Hydrocortisone acetate; Tixocortol; Kappadione; Teicoplanin; Atezolizumab; Gamolenic acid; Upadacitinib | No abstract available | Details |
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S01 | Anti-inflammatory | inflammatory | 5-Aminosalicylates (5-ASAs); corticosteroids | Crohn's disease and ulcerative colitis are the two main com… | Details |
| S02 | Immunosuppression | Classic immunosuppressive drugs | azathioprine; 6-mercaptopurine; methotrexate; ciclosporin-A; tacrolimus | Ciclosporin-A and tacrolimus bind to specific intracellular… | Details |
| S03 | Anti-TNF agents | Tumor necrosis factor | infliximab; adalimumab; golimumab; certolizumab pegol | TNF is produced by various immune and non-immune cells in t… | Details |
| S04 | T-cell homing and retention | T-cell trafficking | vedolizumab; anti-MAdCAM1 antibodies ; etrolizumab | Inhibition of the interaction between α4β7 integrins on T c… | Details |
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
| S08 | Strengthening barrier function | Modulation of barrier function | phosphatidylcholine (lecithin); imiquimod; mongersen | Escherichia coli Nissle (EcN) is a nonpathogenic Gram-negat… | Details |
| S11 | Improveming Intestinal Microecology | the intestinal microbiota | antibiotics; probiotics; prebiotics; postbiotics; synbiotics; fecal microbiota transplantation (FMT) | The imbalance between beneficial bacteria and harmful patho… | Details |
Adjunctive antibiotic therapy with rifaximin may help reduce Crohn's disease ac…
PMID: 20112064
Year: 2010
Relationship Type:
Treatment
Score: 6.1
AIMS: Enteric bacteria are thought to contribute to the pathogenesis of Crohn's disease, and antibiotics may be an effective therapy. This study exam…
Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases
PMID: 19881343
Year: 2010
Relationship Type:
Treatment
Score: 6.1
PURPOSE OF REVIEW: Rifaximin is gaining attention for its potential activity in a multitude of gastrointestinal diseases. We review the unique pharma…
Showing 21-22 of 22 articles